Gen­mab vets at low-pro­file Y-mAbs steer two MSK can­cer drugs to the FDA af­ter land­ing $50M from HBM

Al­most ex­act­ly two years ago, a group of Gen­mab vet­er­ans formed a biotech com­pa­ny called Y-mAbs in New York, launch­ing with a pair of clin­i­cal-stage can­cer drugs snared from sci­en­tists at Memo­r­i­al Sloan-Ket­ter­ing.

To­day, just a few months af­ter grab­bing a break­through drug des­ig­na­tion for the lead ther­a­py in the li­cens­ing pact, Y-mAbs is back with a $50 mil­lion raise from HBM, a promi­nent biotech in­vestor. And it’s aim­ing for a near-term FDA ap­proval of bur­tomab and its oth­er drug from MSK, naxi­ta­m­ab.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.